DCF Advisers’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.06M | Buy |
182,500
+11,500
| +7% | +$193K | 1.42% | 26 |
|
|
2025
Q1 | $2.63M | Buy |
171,000
+23,500
| +16% | +$361K | 1.26% | 27 |
|
|
2024
Q4 | $3.25M | Buy |
147,500
+34,500
| +31% | +$760K | 1.57% | 21 |
|
|
2024
Q3 | $2.04M | Sell |
113,000
-17,750
| -14% | -$320K | 0.81% | 29 |
|
|
2024
Q2 | $2.12M | Buy |
130,750
+45,750
| +54% | +$743K | 1.09% | 29 |
|
|
2024
Q1 | $1.2M | Buy |
85,000
+46,000
| +118% | +$649K | 0.59% | 37 |
|
|
2023
Q4 | $407K | Sell |
39,000
-5,500
| -12% | -$57.4K | 0.22% | 55 |
|
|
2023
Q3 | $454K | Buy |
44,500
+5,500
| +14% | +$56.1K | 0.25% | 54 |
|
|
2023
Q2 | $294K | Buy |
+39,000
| New | +$294K | 0.16% | 65 |
|